Gelteq GELS
NASDAQ GELS
$0.56 +0.01 (+1.13%)
As of: Aug 20, 2026 · 3:22 PM EDT

Gelteq (GELS) Debt Ratio (2023 - 2025)

Gelteq (GELS) posted quarterly Debt Ratio of 0.25 for Q4 2025, up 63.36% year-over-year from 0.16 in Q4 2024, and down 35.27% quarter-over-quarter from 0.39 in Q2 2025.

Gelteq (GELS) Debt Ratio (2023 - 2025) Analysis & Trends

Gelteq's Debt Ratio history runs 3 years deep, the most recent figure standing at 0.25 for Q4 2025.

  • In Q4 2025, Debt Ratio rose 63.36% year-over-year to 0.25; the TTM figure through Dec 2025 stood at 0.25 (up 63.36% YoY), while the FY2025 annual figure was 0.39, up 111.44% from the prior year.
  • Debt Ratio for Q4 2025 stood at 0.25, down from 0.39 in the prior quarter.
  • The five-year high for Debt Ratio was 0.39 in Q2 2025, with the low at 0.11 in Q2 2023.
  • The 3-year median for Debt Ratio is 0.19 (2024), against an average of 0.22.
  • Peak annual rise in Debt Ratio reached 111.44% in 2025, while the deepest fall reached 63.36% in 2025.
  • Gelteq's Debt Ratio stood at 0.11 in 2023, then soared by 40.9% to 0.16 in 2024, then surged by 63.36% to 0.25 in 2025.
  • Business Quant data shows GELS's Debt Ratio at 0.25 in Q4 2025, 0.39 in Q2 2025, and 0.16 in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -0.13
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn 0.42
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn 0.60
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn 0.32
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn -
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn 0.38
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn -
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn 0.29
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - 0.12
10 Gelteq 5.85 Mn 5.58 Mn - 0.25

Historic Data

Download Data
DateValue
Dec 31, 2025 0.25
Jun 30, 2025 0.39
Dec 31, 2024 0.16
Jun 30, 2024 0.19
Jun 30, 2023 0.11